Sandoz On Track To Complete Aurobindo Deal By March
As Firm Completes Acquisition Of Aspen’s Japanese Operations
Sandoz says it expects to close the sale of its US dermatology and oral solids business to Aurobindo by the end of the first quarter of 2020, having seen the deal’s completion date pushed back from 2019.
You may also be interested in...
Sandoz Gains Rights To Two US Injectables
With the $1bn deal to transfer its US dermatology and orals solids operations to Aurobindo still awaiting completion, Sandoz is expanding its portfolio of sterile injectables - a key area of focus for the company - by acquiring the rights to two products from BE Pharmaceuticals.
Aspen Makes Multiple Moves Amid Challenging Conditions
South Africa’s Aspen has made multiple strategic moves, including divesting its Japanese business to Sandoz and selling its local Phekolong Pharmaceuticals South African subsidiary to Laurus Labs, as part of efforts to better position itself in the face of “challenging” market conditions.
FDA Gives Then Rescinds Clearance For Aurobindo Plant
Aurobindo Pharma shares have nosedived after the US Food and Drug Administration said an investigation into one of the Indian drugmaker’s plants was still open, days after issuing a notice giving the site the all-clear.